Observational study of people infected with SARS-Cov-2, treated with amantadine

BACKGROUND: We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. METHODOLOGY: In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Aranda-Abreu, Gonzalo Emiliano, Aranda-Martínez, José D., Araújo, Ramiro, Hernández-Aguilar, María Elena, Herrera-Covarrubias, Deissy, Rojas-Durán, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547815/
https://www.ncbi.nlm.nih.gov/pubmed/33040252
http://dx.doi.org/10.1007/s43440-020-00168-1
Descripción
Sumario:BACKGROUND: We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. METHODOLOGY: In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. RESULTS: This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. CONCLUSION: Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.

Ejemplares similares